Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5801-5808

  Sharma, Sreevalli ^a   Gelman, Ekaterina ^b   Narayan, Chandan ^a,c   Bhattacharjee, Deepa ^a   Achar, Vijayashree ^a   Humnabadkar, Vaishali ^a   Balasubramanian, V ^a,d   Ramachandran, Vasanthi ^a   Dhar, Neeraj ^b   Dinesh, Neela ^a  

^a ASTRAZENECA   (United Kingdom)

^b EPFL   (Switzerland)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d Texas Instruments India Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CHLORAMPHENICOL; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PRETOMANID; PYROXYLIN; TUBERCULOSTATIC AGENT;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERICIDAL ACTIVITY; BINDING SITE; CELL COUNT; CFU COUNTING; CFU ENUMERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BASE COMPOSITION; DRUG DETERMINATION; GENE EXPRESSION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LUCIFERASE ASSAY; LUMINESCENCE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPERON; RESAZURIN BASED MINIMUM BACTERICIDAL CONCENTRATION ASSAY; RIBOSOME; STREPTOMYCES COELICOLOR; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; REPRODUCIBILITY;

ANTITUBERCULAR AGENTS; LUMINESCENT MEASUREMENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84907266460     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03205-14     Document Type: Article

References (29)

1. WHO. 2014. Tuberculosis fact sheet. WHO, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 28 April 2014.
2. Sirgel FA, Wiid IJ, van Helden PD. 2009. Measuring minimum inhibitory concentrations in mycobacteria. Methods Mol. Biol. 465:173-186. http://dx.doi.org/10.1007/978-1-59745-207-6-11.
3. Taneja NK, Tyagi JS. 2007. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J. Antimicrob. Chemother. 60:288-293. http://dx.doi.org/10 .1093/jac/dkm207.
4. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362-366.
5. Kontos F, Maniati M, Costopoulos C, Gitti Z, Nicolaou S, Petinaki E, Anagnostou S, Tselentis I, Maniatis AN. 2004. Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study. J. Microbiol. Methods 56:291-294. http://dx.doi.org/10.1016/j.mimet.2003.10 .015.
6. Meighen EA. 1991. Molecular biology of bacterial bioluminescence. Microbiol. Rev. 55:123-142.
7. Andrew PW, Roberts IS. 1993. Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents. J. Clin. Microbiol. 31:2251-2254.
8. Cooksey RC, Crawford JT, Jacobs WR, Jr, Shinnick TM. 1993. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. 37:1348-1352. http://dx.doi.org/10.1128/AAC.37.6 .1348.
9. Arain TM, Resconi AE, Hickey MJ, Stover CK. 1996. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob. Agents Chemother. 40:1536-1541.
10. Hickey MJ, Arain TM, Shawar RM, Humble DJ, Langhorne MH, Morgenroth JN, Stover CK. 1996. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob. Agents Chemother. 40:400-407.
11. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, Young DB. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67:4586-4593.
12. Deb DK, Srivastava KK, Srivastava R, Srivastava BS. 2000. Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem. Biophys. Res. Commun. 279:457-461. http://dx .doi.org/10.1006/bbrc.2000.3957.
13. Heuts F, Carow B, Wigzell H, Rottenberg ME. 2009. Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect. 11:1114-1121. http://dx.doi.org/10.1016/j.micinf.2009.08.005.
14. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10777. http://dx.doi.org/10.1371/journal.pone.0010777.
15. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. 2012. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J. Antimicrob. Chemother. 67:404-414. http://dx.doi.org/10.1093/jac/dkr472.
16. Zhang T, Li SY, Nuermberger EL. 2012. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One 7:e29774. http://dx.doi.org/10.1371/journal .pone.0029774.
17. Andreu N, Zelmer A, Sampson SL, Ikeh M, Bancroft GJ, Schaible UE, Wiles S, Robertson BD. 2013. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. J. Antimicrob. Chemother. 68:2118-2127. http://dx.doi.org/10.1093/jac /dkt155.
18. Craney A, Hohenauer T, Xu Y, Navani NK, Li Y, Nodwell J. 2007. A synthetic luxCDABE gene cluster optimized for expression in high-GC bacteria. Nucleic Acids Res. 35:e46. http://dx.doi.org/10.1093/nar /gkm086.
19. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, Riley LW, Schnappinger D. 2005. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 33:e21. http://dx.doi.org/10.1093/nar/gni013.
20. Lee MH, Pascopella L, Jacobs WR, Jr, Hatfull GF. 1991. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and Bacille Calmette-Guerin. Proc. Natl. Acad. Sci. U. S. A. 88:3111-3115. http://dx .doi.org/10.1073/pnas.88.8.3111.
21. Clinical and Laboratory Standards Institute. 2008. Laboratory detection and identification of mycobacteria; approved guideline. CLSI document M48-A. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Schultz DW, Yarus M. 1990. A simple and sensitive in vivo luciferase assay for tRNA-mediated nonsense suppression. J. Bacteriol. 172:595-602.
23. Holzman TF, Baldwin TO. 1982. Isolation of bacterial luciferases by affinity chromatography on 2, 2-diphenylpropylamine-Sepharose: phosphate- mediated binding to an immobilized substrate analogue. Biochemistry 21:6194-6201. http://dx.doi.org/10.1021/bi00267a026.
24. Roberts EA, Clark A, Friedman RL. 2005. Bacterial luciferase is naturally destabilized in Mycobacterium tuberculosis and can be used to monitor changes in gene expression. FEMS Microbiol. Lett. 243:243-249. http://dx .doi.org/10.1016/j.femsle.2004.12.010.
25. Rastogi N, Goh KS, David HL. 1989. Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein- Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res. Microbiol. 140:405-417. http://dx.doi.org/10.1016/0923 -2508(89)90016-8.
26. Garrigó M, Aragon LM, Alcaide F, Borrell S, Cardenosa E, Galan JJ, Gonzalez-Martin J, Martin-Casabona N, Moreno C, Salvado M, Coll P. 2007. Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:1766-1770. http://dx.doi.org/10.1128 /JCM.02162-06.
27. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56: 5782-5789. http://dx.doi.org/10.1128/AAC.01125-12.
28. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, van Soolingen D, Bakker-Woudenberg IA. 2010. Timekill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65:2582-2589. http://dx.doi.org/10.1093/jac/dkq374.
29. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201. http://dx.doi.org/10 .1086/510247.